<code id='10489F6241'></code><style id='10489F6241'></style>
    • <acronym id='10489F6241'></acronym>
      <center id='10489F6241'><center id='10489F6241'><tfoot id='10489F6241'></tfoot></center><abbr id='10489F6241'><dir id='10489F6241'><tfoot id='10489F6241'></tfoot><noframes id='10489F6241'>

    • <optgroup id='10489F6241'><strike id='10489F6241'><sup id='10489F6241'></sup></strike><code id='10489F6241'></code></optgroup>
        1. <b id='10489F6241'><label id='10489F6241'><select id='10489F6241'><dt id='10489F6241'><span id='10489F6241'></span></dt></select></label></b><u id='10489F6241'></u>
          <i id='10489F6241'><strike id='10489F6241'><tt id='10489F6241'><pre id='10489F6241'></pre></tt></strike></i>

          Home / hotspot / entertainment

          entertainment


          entertainment

          author:hotspot    Page View:4
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

          Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

          advertisement

          The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In